Aims and Scope
mAbs is a peer-reviewed multi-disciplinary scientific journal established in 2009, published by Taylor & Francis and dedicated to the art and science of antibody research and development. Its editor-in-chief is Janice M. Reichert and it is affiliated with The Antibody Society. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. It is indexed in MEDLINE, PubMed, the Science Citation Index Expanded, Biological Abstracts, BIOSIS Previews, and Scopus.
Key Metrics
10.2
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.01 - 0.05
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
5 - 10
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.93
5-Year SI
5-year SI
- N/A 2-year SI
- 0.94 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Immunology
SJR
- Q1 Immunology
- Q1 Immunology and Allergy
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.55
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Biosimilar
- Monoclonal antibody
- Immunoglobulin G
- Heavy chain
- Bispecific antibody
- Dual targeting
- Lymph node
- Mass spectrometry
- Central nervous system
- Crystal structure
- Antitumor response
- Biopharmaceutical
- High affinity binding
- Phage display
- Inflammatory arthritis
- Protective antibody
- Target antigen
- Sequence analysis
- Antigen binding
- Tumor microenvironment
Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS INC |
| Language | English |
| Frequency | Bi-monthly |
| Article Processing Charges | GBP 2915 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2009 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 8 |
| Article Processing Charges | GBP 2915 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in mAbs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Do antibody CDR loops change conformation upon binding?
- 31 Dec 24
- mAbs
-
Full paper
Enrichment strategy and initial characterization of heterodimers enriched from a co-formulated cocktail of therapeutic antibodies against SARS-COV-2
- 9 Apr 24
- mAbs
-
Full paper
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches
- 28 Mar 24
- mAbs
-
Full paper
Correction
- 28 Mar 24
- mAbs
-
Full paper
Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry
- 27 Mar 24
- mAbs
-
Full paper
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
- 27 Mar 24
- mAbs
Scite analysis
Powered by scite_
1.6k articles received 51.8k citations see all
- 1,484 Supporting
- 49,891 Mentioning
- 88 Contrasting
Editorial notices
- 1 Retractions
- 0 Withdrawals
- 13 Corrections
- 13 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
17%
4 to 6 months
67%
7 to 9 months
17%
Above 9 months
0%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has mAbs been actively publishing?
mAbs has been in operation since 2009 till date.
What is the publishing frequency of mAbs ?
mAbs published with a Bi-monthly frequency.
How many articles did mAbs publish last years ?
In 2023, mAbs published 95 articles.
What is the eISSN & pISSN for mAbs ?
For mAbs,eISSN is 1942-0870 and pISSN is1942-0862.
What is Citescore for mAbs ?
Citescore for mAbs is 10.2.
What is SNIP score for mAbs ?
SNIP score for mAbs is 1.55.
What is the SJR for mAbs ?
SJR for mAbs is Q1.
Who is the publisher of mAbs ?
TAYLOR & FRANCIS INC is the publisher of mAbs.